1. Home
  2. MX vs ADCT Comparison

MX vs ADCT Comparison

Compare MX & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magnachip Semiconductor Corporation

MX

Magnachip Semiconductor Corporation

HOLD

Current Price

$3.72

Market Cap

139.1M

Sector

Technology

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.12

Market Cap

136.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MX
ADCT
Founded
2003
2011
Country
South Korea
Switzerland
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.1M
136.1M
IPO Year
2007
2019

Fundamental Metrics

Financial Performance
Metric
MX
ADCT
Price
$3.72
$1.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$5.75
$7.75
AVG Volume (30 Days)
1.0M
878.2K
Earning Date
04-28-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
43.06
30.86
EPS
N/A
N/A
Revenue
$178,860,000.00
$81,357,000.00
Revenue This Year
$8.55
N/A
Revenue Next Year
$6.37
$66.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.85
52 Week Low
$2.18
$0.78
52 Week High
$9.86
$4.98

Technical Indicators

Market Signals
Indicator
MX
ADCT
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
MX
ADCT

About MX Magnachip Semiconductor Corporation

MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The Company operates within a single operating segment, Power Solutions business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: